Company
OSE Immunotherapeutics
OSE Immunotherapeutics has 1 drug tracked on RxWires: 1 in Phase 3.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| OSE2101 | Phase 3 | Patients With Non-Small Cell Lung Cancer |
Latest
No recent events.
Follow OSE Immunotherapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.